Provectus Biopharmaceuticals, Inc. (Provectus) has unveiled VisiRose, Inc. (VisiRose), marking its venture into founded entities. This newly established clinical-stage biotech firm is dedicated to advancing the commercialization of Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT) targeting infectious keratitis and other severe ocular infections. The therapy utilizes Provectus’s synthetic small molecule and active pharmaceutical ingredient (API), Rose Bengal Sodium (RBS). The University of Miami holds a minor equity stake in VisiRose.
RB PDAT is a pioneering, non-invasive investigational therapeutic approach for ocular infections, informed by cutting-edge research from the Ophthalmic Biophysics Center at the Bascom Palmer Eye Institute (BPEI), part of the University’s Miller School of Medicine. This treatment fuses Provectus’s RBS API with OBC’s light-emitting medical device to combat bacterial, fungal, and parasitic infections, including those resistant to multiple drugs.
Dominic Rodrigues, interim CEO of VisiRose and acting president and vice chairman of Provectus, stated, “RB PDAT offers a vital alternative for those facing vision impairment due to infectious keratitis. We are confident that this breakthrough therapy merges targeted anti-infective actions with vision-saving benefits, heralding a promising future for individuals dealing with this challenging condition.”
Ed Pershing, chairman for both VisiRose and Provectus, remarked, “VisiRose is a testament to Provectus’s innovative approach, linking creativity and effectiveness. By spinning off this dedicated ophthalmic entity, we strengthen our capacity to meet unmet medical necessities while adding value for shareholders. As we target the flourishing field of eye care, we further the development of RB PDAT while enhancing the inherent worth of RBS and optimizing Provectus’s market standing.”
VisiRose represents a collaboration between the University of Miami and Provectus Biopharmaceuticals, emphasizing the application of state-of-the-art ocular research from the Miller School of Medicine’s Bascom Palmer Eye Institute and its Ophthalmic Biophysics Center using Provectus’s RBS.
The Bascom Palmer Eye Institute operates as the University of Miami Miller School of Medicine’s Ophthalmology Department. Its objectives focus on boosting life quality by enhancing vision, preventing blindness, and expanding ophthalmic insights through exceptional patient care and pioneering research.
Provectus Biopharmaceuticals, an innovative clinical-stage biotech organization, is crafting immunotherapy solutions for an array of conditions, based on its portfolio of bioactive synthetic small molecules known as halogenated xanthenes.